DR. JASON GOTLIB, M.D., M.S.
Osteopathic Medicine at Blake Wilbur Dr, Palo Alto, CA
License number
California A060833
Category
Osteopathic Medicine
Type
Hematology
Address
Address
875 Blake Wilbur Dr RM 2327B, Palo Alto, CA 94304
Phone
(650) 736-1253
(650) 724-5203 (Fax)
(650) 724-5203 (Fax)
Organization information
See more information about JASON GOTLIB at bizstanding.comJason Gotlib MD,MS
875 Blake Wilbur Dr, Palo Alto, CA 94304
Industry:
Hematologists, Oncology, Internist
Site:
Phone:
(650) 498-6000 (Phone)
Description:
There are 10 doctors at this site. Surgery is not performed at this site.
Jason Robert Gotlib
Professional information
Dr. Jason Gotlib, Palo Alto CA - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
703 Welch Rd STE G1, Palo Alto 94304
(650) 736-1204 (Phone)
Stanford Clinical Cancer Center
875 Blake Wilbur Dr, Palo Alto 94304
(650) 498-6000 (Phone)
(650) 736-1204 (Phone)
Stanford Clinical Cancer Center
875 Blake Wilbur Dr, Palo Alto 94304
(650) 498-6000 (Phone)
Certifications:
Hematology, 2001, Internal Medicine, 1998, Medical Oncology, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
703 Welch Rd STE G1, Palo Alto 94304
Stanford Clinical Cancer Center
875 Blake Wilbur Dr, Palo Alto 94304
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Stanford Clinical Cancer Center
875 Blake Wilbur Dr, Palo Alto 94304
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford 94305
Education:
Medical School
Stanford University School Of Medicine
Graduated: 1995
Stanford University School Med
Graduated: 1996
Graduated: 1998
Graduated: 2000
Stanford University School Of Medicine
Graduated: 1995
Stanford University School Med
Graduated: 1996
Graduated: 1998
Graduated: 2000
Mutations In The Lnk Gene In Patients With Myeloproliferative Neoplasms And Other Hematolymphoid Malignancies
US Patent:
2012004, Feb 23, 2012
Filed:
Jan 12, 2011
Appl. No.:
13/005455
Inventors:
Jason Robert Gotlib - Palo Alto CA, US
Garry P. Nolan - San Francisco CA, US
James L. Zehnder - Menlo Park CA, US
Stephen Tracy Oh - St. Luis MO, US
Garry P. Nolan - San Francisco CA, US
James L. Zehnder - Menlo Park CA, US
Stephen Tracy Oh - St. Luis MO, US
International Classification:
A61K 38/02, A61P 35/00, C12Q 1/02, C12Q 1/68, G01N 33/566
US Classification:
514 193, 435 61, 435 611, 435 612, 435 721, 435 29, 514 192
Abstract:
Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
Jason Robert Gotlib, Stanford CA
Specialties:
Internal Medicine, Hematology & Oncology, Hematology, Medical Oncology, Hematology
Work:
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford, CA 94305
300 Pasteur Dr, Stanford, CA 94305
Education:
Stanford University (1995)
Jason Gotlib, Palo Alto CA
Specialties:
Oncologist
Address:
875 Blake Wilbur Dr, Palo Alto, CA 94304
Wnt Pathway Mutations In Cancer Stem Cells
US Patent:
2010028, Nov 11, 2010
Filed:
Nov 2, 2007
Appl. No.:
12/447884
Inventors:
Catriona Helen M. Jamieson - La Jolla CA, US
Ifat Geron - San Diego CA, US
Annelie Abrahamsson - San Diego CA, US
Edward Kavalerchik - San Diego CA, US
Irving L. Weissman - Stanford CA, US
Jason Gotlib - Stanford CA, US
Ifat Geron - San Diego CA, US
Annelie Abrahamsson - San Diego CA, US
Edward Kavalerchik - San Diego CA, US
Irving L. Weissman - Stanford CA, US
Jason Gotlib - Stanford CA, US
International Classification:
C12Q 1/48, C12Q 1/68, G01N 33/573, A01K 67/00
US Classification:
800 10, 435 15, 435 6, 435 74
Abstract:
Cancer specific splicing events in the Wnt/β-catenin signaling pathway are associated with progression of myelogenous leukemia. Misspliced genes of interest include GSK3β. In some embodiments of the invention, polynucleotides are provided that correspond to misspliced GSK3β transcripts associated with cancer. Such transcripts are characterized by a deletion of exon (8), and particularly in exon (8) and (9). Detection of such transcripts in cells is indicative of the presence of leukemia, and particularly of the presence of leukemia stem cells. In other embodiments, polypeptides are provided that are encoded by misspliced GSK3β transcripts associated with cancer. Such polypeptides are useful as diagnostic markers for cancer, and as a target for screening of therapeutic agents. Animal models comprising a human LSC having a misspliced GSK3b transcript provide a useful model for leukemia, for drug/gene screening in the prevention and treatment of leukemia in humans, etc.